Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 475.00 |
Expiry date | 2024-05-03 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 62 |
McKesson Corp reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company's branded and specialty drugs that dragged sales in its U.S. pharmaceutical segment. The segment also sells branded and generic drugs, as well as over-the-counter products and vaccines. Sales in the segment rose 11.5% in the fourth quarter to $68.79 billion, but missed analysts' estimate of $71.65 billion, according to LSEG data.
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insights into McKesson's Financial Performance and Future Outlook